Bibliographic
This study aims at evaluating the disease-modifying efficacy on cognitive and behavioral outcomes in the APP23 transgenic mouse model of AD. Chronic ibuprofen administration started at the young age of 6 weeks, prior to the development of cognitive impairment and the appearance of plaques, and continued until the age of 18 weeks, thereby, sufficiently surpassing the age at which severe cognitive impairment is present under basal conditions. At age 6 weeks, heterozygous APP23 mice and control littermates were subcutaneously implanted with osmotic pumps delivering saline or ibuprofen (50 mg/kg daily). After 2 months of treatment, a 3-week washout period prevented bias from potential symptomatic effects before cognitive evaluation commenced, using the Morris water Maze Test. Data show that ibuprofen-treated APP23 mice performed significantly better than their sham-treated counterparts and almost attained the same level of performance as control animals on a complex visual-spatial learning task.